Cao Y et al. Mosunetuzumab and lymphoma: Latest updates from 2022 ASH annual meeting. J Hematol Oncol 2023;16(1):69. Abstract

Crombie JL et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 2024;143(16):1565-75. Abstract

Falchi L et al. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood 2023;141(5):467-80. Abstract

Raje N et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer J 2023;13(1):116. Abstract

Shirley M. Glofitamab: First approval. Drugs 2023;83(10):935-41. Abstract

Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract

Villasboas JC et al. Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with extended follow-up. Blood 2023;142(Suppl 1):3041. Abstract

Weddell J. Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. CPT Pharmacometrics Syst Pharmacol 2023;12(11):1726-37. Abstract